Anuh Pharma surges on getting CEP for Sulfadimethoxine from EDQM
Anuh Pharma is currently trading at Rs. 82.03, up by 2.87 points or 3.63% from its previous closing of Rs. 79.16 on the BSE.
The scrip opened at Rs. 79.30 and has touched a high and low of Rs. 83.25 and Rs. 79.00 respectively. So far 14891 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 121.00 on 20-Dec-2024 and a 52 week low of Rs. 74.03 on 18-Mar-2025.
Last one week high and low of the scrip stood at Rs. 83.25 and Rs. 78.27 respectively. The current market cap of the company is Rs. 824.14 crore.
The promoters holding in the company stood at 71.82%, while Non-Institutions held 28.18% in the company.
Anuh Pharma has been granted the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for Sulfadimethoxine. This approval reinforces Anuh Pharma’s commitment to delivering high-quality Active Pharmaceutical Ingredients that adhere to the most stringent global regulatory standards. The CEP for Sulfadimethoxine will enable expanded access to regulated markets and support its customers with enhanced reliability, compliance, and supply security.
Established in 1960, Anuh Pharma is one of the largest manufacturers of Macrolides and Anti-TB products in India.
